<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189279</url>
  </required_header>
  <id_info>
    <org_study_id>192024-053</org_study_id>
    <nct_id>NCT01189279</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, and pharmacokinetics of new
      formulation of bimatoprost following topical application in patients with alopecia. Two
      formulations of bimatoprost will be investigated in Part 1 and a third formulation of
      bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax is the maximum plasma level following a single dose of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost</measure>
    <time_frame>17 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax is the maximum plasma level following multiple doses of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>17 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>An ECG is a tracing of the heart's electrical activity over time in waves with points identified at P, Q, R, S, and T [measured in milliseconds (ms)], as well as the heart rate [measured in beats per minute (bpm)]. Clinically significant abnormal results include maximum post-treatment QTcB&gt;500 ms, maximum post-treatment QTcF&gt;500 ms, maximum post-treatment QT interval &gt;500 ms, PR interval 25% increase from baseline and &gt;200 ms, QRS interval 25% increase from baseline and &gt;100 ms, heart rate 25% increase from baseline and &gt;100 bpm, and heart rate 25% decrease from baseline and &lt;50 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Patient Assessment</measure>
    <time_frame>Baseline, 20 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local scalp tolerability by patient assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 3 symptoms (burning, itching, and stinging). An at least 1-grade increase from baseline at any timepoint indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Dermatologist Assessment</measure>
    <time_frame>Baseline, 20 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local scalp tolerability by dermatologist assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 5 symptoms (dryness/scaling, edema, erythema, folliculitis, and pigmentation). An at least 1-grade increase at any timepoint from baseline indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Alopecia</condition>
  <condition>Alopecia, Androgenetic</condition>
  <condition>Baldness</condition>
  <arm_group>
    <arm_group_label>Part 1: bimatoprost Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: bimatoprost Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: bimatoprost Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation A</intervention_name>
    <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
    <arm_group_label>Part 1: bimatoprost Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation B</intervention_name>
    <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
    <arm_group_label>Part 1: bimatoprost Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation C</intervention_name>
    <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
    <arm_group_label>Part 2: bimatoprost Formulation C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males with moderate male-pattern baldness (androgenic alopecia)

          -  Females with moderate female pattern hair loss

          -  Non-smoker or smoker with at least 30 days abstinence from smoking/using
             nicotine-containing products

        Exclusion Criteria:

          -  Any dermatological condition of the scalp other than androgenic alopecia (males) or
             female pattern hair loss (females)

          -  Use of bimatoprost or other prostaglandin analogs within 3 months

          -  Prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months

          -  Any prior hair growth procedures (eg, hair transplant or laser)

          -  Blood donation or equivalent blood loss within 90 days

          -  History of alcohol or drug addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>August 25, 2010</firstreceived_date>
  <firstreceived_results_date>June 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part 1 of the study was double-blind, followed by Part 2 which was open-label. No patients enrolled in Part 1 were enrolled in Part 2 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Bimatoprost Formulation A</title>
          <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Bimatoprost Formulation B</title>
          <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="P3">
          <title>Part 2: Bimatoprost Formulation C</title>
          <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Bimatoprost Formulation A</title>
          <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Bimatoprost Formulation B</title>
          <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="B3">
          <title>Part 2: Bimatoprost Formulation C</title>
          <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;45 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 to 64 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost</title>
        <description>Cmax is the maximum plasma level following a single dose of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all subjects with no major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Bimatoprost Formulation A</title>
            <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Bimatoprost Formulation B</title>
            <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Bimatoprost Formulation C</title>
            <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost</title>
            <description>Cmax is the maximum plasma level following a single dose of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
            <units>Picograms/Milliliter (pg/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.552" spread="0.575"/>
                  <measurement group_id="O2" value="1.77" spread="1.11"/>
                  <measurement group_id="O3" value="5.58" spread="3.66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost</title>
        <description>Cmax is the maximum plasma level following multiple doses of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
        <time_frame>17 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all subjects with no major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Bimatoprost Formulation A</title>
            <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Bimatoprost Formulation B</title>
            <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Bimatoprost Formulation C</title>
            <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost</title>
            <description>Cmax is the maximum plasma level following multiple doses of bimatoprost. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
            <units>Picograms/Milliliter (pg/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.26" spread="0.60"/>
                  <measurement group_id="O2" value="3.01" spread="1.66"/>
                  <measurement group_id="O3" value="10.1" spread="7.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>An ECG is a tracing of the heart's electrical activity over time in waves with points identified at P, Q, R, S, and T [measured in milliseconds (ms)], as well as the heart rate [measured in beats per minute (bpm)]. Clinically significant abnormal results include maximum post-treatment QTcB&gt;500 ms, maximum post-treatment QTcF&gt;500 ms, maximum post-treatment QT interval &gt;500 ms, PR interval 25% increase from baseline and &gt;200 ms, QRS interval 25% increase from baseline and &gt;100 ms, heart rate 25% increase from baseline and &gt;100 bpm, and heart rate 25% decrease from baseline and &lt;50 bpm.</description>
        <time_frame>17 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all subjects who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Bimatoprost Formulation A</title>
            <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Bimatoprost Formulation B</title>
            <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Bimatoprost Formulation C</title>
            <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Clinically Significant Electrocardiogram (ECG) Findings</title>
            <description>An ECG is a tracing of the heart's electrical activity over time in waves with points identified at P, Q, R, S, and T [measured in milliseconds (ms)], as well as the heart rate [measured in beats per minute (bpm)]. Clinically significant abnormal results include maximum post-treatment QTcB&gt;500 ms, maximum post-treatment QTcF&gt;500 ms, maximum post-treatment QT interval &gt;500 ms, PR interval 25% increase from baseline and &gt;200 ms, QRS interval 25% increase from baseline and &gt;100 ms, heart rate 25% increase from baseline and &gt;100 bpm, and heart rate 25% decrease from baseline and &lt;50 bpm.</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="20.238"/>
                  <measurement group_id="O2" value="0.0" spread="23.460"/>
                  <measurement group_id="O3" value="0.0" spread="19.667"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Patient Assessment</title>
        <description>Local scalp tolerability by patient assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 3 symptoms (burning, itching, and stinging). An at least 1-grade increase from baseline at any timepoint indicates a worsening of symptoms.</description>
        <time_frame>Baseline, 20 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all subjects who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Bimatoprost Formulation A</title>
            <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Bimatoprost Formulation B</title>
            <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Bimatoprost Formulation C</title>
            <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Patient Assessment</title>
            <description>Local scalp tolerability by patient assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 3 symptoms (burning, itching, and stinging). An at least 1-grade increase from baseline at any timepoint indicates a worsening of symptoms.</description>
            <units>Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Burning</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Itching</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stinging</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Dermatologist Assessment</title>
        <description>Local scalp tolerability by dermatologist assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 5 symptoms (dryness/scaling, edema, erythema, folliculitis, and pigmentation). An at least 1-grade increase at any timepoint from baseline indicates a worsening of symptoms.</description>
        <time_frame>Baseline, 20 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all subjects who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Bimatoprost Formulation A</title>
            <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Bimatoprost Formulation B</title>
            <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Bimatoprost Formulation C</title>
            <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Dermatologist Assessment</title>
            <description>Local scalp tolerability by dermatologist assessment is based on a 4-point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe) for 5 symptoms (dryness/scaling, edema, erythema, folliculitis, and pigmentation). An at least 1-grade increase at any timepoint from baseline indicates a worsening of symptoms.</description>
            <units>Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Dryness/Scaling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Folliculitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pigmentation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Bimatoprost Formulation A</title>
          <description>bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Bimatoprost Formulation B</title>
          <description>bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
        <group group_id="E3">
          <title>Part 2: Bimatoprost Formulation C</title>
          <description>bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application Site Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
